2nd Annual Conference on Nutritional Ketosis and Metabolic Therapeutics

February 1-4, 2017
Embassy Suites USF, Tampa, Florida
Epigenix Foundation is a 501(c)(3) Guidestar Platinum Rated organization that was founded in 2016 with a mission to understand the epigenetic impact of metabolic interventions on human disease and performance. Our team is dedicated to studying how nutrition can determine the way in which our “genetic predispositions” are expressed and can be altered through the choices we make. We are currently focused on validating the efficacy of the ketogenic diet and its application in addressing cancer and other metabolic diseases.

For more information please visit: www.epigenixfoundation.org
Thank you for joining us at the Conference on Nutritional Ketosis and Metabolic Therapeutics! This event is only possible because of your attendance!

This week you’ll have the opportunity to engage with international experts on metabolic therapies, and we invite you to share your thoughts and participate in the conversation. It starts with a single question, but it takes a collective effort to find the answer.

We sincerely appreciate your interest in this event, and the generous support of our sponsors!

In good health,
The Planning Committee

“Creativity is the power to reject the past, to change the status quo, and to seek new potential.” – Ai Weiwei
PRESENTING SPONSOR
Epigenix Foundation

PLATINUM SPONSORS
Quest Keto

GOLD SPONSORS
Prüvit

SILVER SPONSORS
KetoSports Inc
The Nisshin-OilliO Group, Ltd.

BRONZE SPONSORS
The Charlie Foundation
MaxLove Project
METFLEX
Dry Farm Wines
Bulletproof
Restore
KetoVie
Le Gamberi Ketogenic Foods
Senza
VitaFlo USA
Terra Biological LLC
Medica Nutrition
Best Answer for Cancer Foundation
Ample Foods
Kegenix
Keto Kookie
Dr. Reinwald Healthcare
Liv-Pro®
Ketogenic.com
Vios Health
**Wednesday, February 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 - 6:00 pm</td>
<td>Check-In; Exhibitor Session (A-G Foyer)</td>
</tr>
<tr>
<td>6:00 - 6:15 pm</td>
<td>Welcome and Introduction - Dominic D’Agostino, Ph.D. (Salon DEFG)</td>
</tr>
<tr>
<td>6:15 - 7:15 pm</td>
<td>Conference Keynote Talk – Vishwa Deep Dixit, D.V.M., Ph.D., Targeting Inflammasome-Mediated Diseases with Ketone Metabolites (Salon DEFG)</td>
</tr>
<tr>
<td>7:15 - 9:00 pm</td>
<td>Welcome Reception with Light Bites (Waterfall Atrium) – Sponsored by Pruvit, Tasting by Dry Farm Wines</td>
</tr>
</tbody>
</table>

**Thursday, February 2**

**Joint Session – Salon DEFG**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 - 10:00 am</td>
<td>Eric C. Westman, M.D., M.H.S., Update on Ketogenic Diet for Obesity, Diabetes, and Metabolic Syndrome</td>
</tr>
<tr>
<td>10:00 - 11:00 am</td>
<td>Stephen Cunnane, Ph.D., Positive Impact of MCT on Neurometabolic and Cognitive Outcomes in MCI: Preliminary Results of a Randomized, Controlled Trial</td>
</tr>
<tr>
<td>11:00 am - 12:00 pm</td>
<td>Adrienne Scheck, Ph.D., The Ketogenic Diet for Glioma: Fighting the Perfect Storm</td>
</tr>
<tr>
<td>12:00 - 12:30 pm</td>
<td>Laszlo Boros, M.D., Genetically Claimed Metabolic Drugs: the Illusion of Genomic Personalized Medicine</td>
</tr>
<tr>
<td>12:30 - 2:00 pm</td>
<td>Lunch Break/Exhibitor Session (A-G Foyer)</td>
</tr>
</tbody>
</table>

**Breakout Room 1 - Metabolic Therapies for Neurological Diseases – Salon DE**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 - 3:00 pm</td>
<td>Mary Newport, M.D., Medium Chain Triglycerides and Ketones for Alzheimer’s and Other Disorders</td>
</tr>
<tr>
<td>3:00 - 3:30 pm</td>
<td>Balázs Győrfy, M.S., Mitochondrial Dysfunction Underlies the Elimination of Synapses Mediated by the Complement System in the Brain</td>
</tr>
<tr>
<td>3:30 - 4:30 pm</td>
<td>Susan Masino, Ph.D., Brain Health and Homeostasis: Ketogenic Diet, Autism, and Adenosine</td>
</tr>
</tbody>
</table>

**Breakout Room 2 - Metabolic Therapies for Cancer I – Salon FG**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 - 2:20 pm</td>
<td>Angela Poff, Ph.D., “Where are we in 2017? The State of the Evidence for the Ketogenic Diet and Cancer.”</td>
</tr>
<tr>
<td>2:20 - 3:00 pm</td>
<td>Eugene Fine, M.D., Ketosis and Cancer in Cells, Animals, and People: A Program for Translational Approach to Therapy (and Prevention?)</td>
</tr>
<tr>
<td>3:00 - 3:30 pm</td>
<td>Rainer Klement, Ph.D., Fats and Physics – Adding a Ketogenic Diet to Radiation Therapy in Cancer Treatment</td>
</tr>
<tr>
<td>3:30 - 4:30 pm</td>
<td>Valter Longo, Ph.D., Fasting Dependent Differential Stress Resistance and Sensitization in Cancer Treatment</td>
</tr>
<tr>
<td>4:30 - 5:00 pm</td>
<td>Young Ko, Ph.D., Understanding and Targeting Cancer Cell Energy Metabolism</td>
</tr>
<tr>
<td>5:00 - 5:30 pm</td>
<td>Brent Reynolds, Ph.D., An Ecological Approach to Diet Based Cancer Therapies</td>
</tr>
</tbody>
</table>

**Joint Sessions**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 - 6:00 pm</td>
<td>Coffee in Exhibitor Hall (A-G Foyer)</td>
</tr>
<tr>
<td>4:30 - 6:30 pm</td>
<td>Exhibitor Session (A-G Foyer), Tasting by Dry Farm Wines</td>
</tr>
</tbody>
</table>
### Friday, February 3

#### Breakout Room 1 - Metabolic Therapies for Obesity, Diabetes, and Metabolic Syndrome – Salon DE

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Presentation Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 am</td>
<td>David Diamond, Ph.D.</td>
<td>A Rigorous Assessment of the Myth that Elevated Serum Cholesterol Causes Cardiovascular Disease</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Jeff Volek, Ph.D.</td>
<td>Keto-adaptation Counteracts Insulin Resistance and Reverses Type-2 Diabetes</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Keith Runyan, M.D.</td>
<td>Management of Type 1 Diabetes with a Ketogenic Diet</td>
</tr>
<tr>
<td>11:45 am</td>
<td>Richard Feinman, Ph.D.</td>
<td>What’s Really Wrong with Medical Research and How to Fix it</td>
</tr>
</tbody>
</table>

#### Breakout Room 2 - Metabolic Therapies for Seizure Disorders – Salon FG

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Presentation Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 am</td>
<td>Eric Kossoff, M.D. and Mackenzie Cervenka, M.D.</td>
<td>Ketogenic Diet Therapy for Epilepsy Across the Ages: Opportunities and Challenges</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Stephenie Clarlone, Ph.D.</td>
<td>Ketone Ester Supplementation in the Angelman Syndrome Mouse Model</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Coffee in Exhibitor Hall (A-G Foyer)</td>
<td></td>
</tr>
<tr>
<td>11:00 am</td>
<td>Zsolt Kovács, Ph.D.</td>
<td>Effect of Ketone Supplementation on Absence Epileptic Seizures and Anxiety in the WAG/Rj Rat Model</td>
</tr>
<tr>
<td>11:30 am</td>
<td>Harry Whelan, M.D.</td>
<td>Ketogenic Diet for Prevention of Central Nervous System Oxygen Toxicity in Closed-Circuit Oxygen Rebreather Diving</td>
</tr>
<tr>
<td>12:00 pm</td>
<td>Panel Discussion Seizure Disorders</td>
<td></td>
</tr>
</tbody>
</table>

#### Joint Sessions

- 12:30 – 2:00 pm: Lunch Break/Exhibitor Session

#### Breakout Room 1 - Metabolic Therapies for Cancer II – Salon DE

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Presentation Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 pm</td>
<td>Christos Chinopoulos, M.D., Ph.D.</td>
<td>Mitochondrial Substrate-Level Phosphorylation as a Potential Bioenergetic Bail-In Mechanism in Cancer</td>
</tr>
<tr>
<td>2:30 pm</td>
<td>Thomas Seyfried, Ph.D.</td>
<td>Press-Pulse: A Novel Therapeutic Strategy for the Metabolic Management of Cancer</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Colin Champ, M.D.</td>
<td>Cancer Prevention Through Dietary Manipulation - Tangible Takeaways</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Andrew Koutnik, B.S.</td>
<td>Cancer Cachexia: Current and Future Therapeutics</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>Ron Penna, B.S., Shannon Kesi, Ph.D., Jethro Hu, M.D.</td>
<td>Epigenix Foundation: An Update on the Effects of Ketogenic Diets in Canine and Human Studies</td>
</tr>
</tbody>
</table>

#### Breakout Room 2 - Metabolic Optimization of Athletic Performance – Salon FG

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Presentation Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 pm</td>
<td>Jeff Volek, Ph.D.</td>
<td>Relevance of Keto-adaptation for Augmenting Human Performance and Resilience</td>
</tr>
<tr>
<td>2:30 pm</td>
<td>Jacob Wilson, Ph.D.</td>
<td>Emerging Areas of Physical Performance Across Lifespan</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Brendan Egan, Ph.D.</td>
<td>Fueling Athletic Performance: From Carbs to Ketones</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>Athletic Performance Panel Session</td>
<td></td>
</tr>
</tbody>
</table>

#### Joint Sessions

- 5:00 - 6:30 pm: Poster Session (Waterfall Atrium)
- 5:00 – 6:30 pm: Reception and Exhibitor Session (A-G Foyer, Waterfall Atrium), Tasting by Dry Farm Wines
- 6:00 – 9:00 pm: Dinner and Entertainment (Salon DEFG) – Sponsored by Quest Keto

### Saturday, February 4

#### Joint Sessions – Salon DE/FG

#### Implementation of Ketogenic Metabolic Therapies

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Presentation Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 am</td>
<td>Miriam Kalamian, M.S.</td>
<td>Responding to Diet Saboteurs, Critics, and Skeptics</td>
</tr>
<tr>
<td>9:45 am</td>
<td>Beth Zupec-Kania, R.D.</td>
<td>Eating Ketogenically with Optimal Nutrition</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Patricia Daly, M.S.</td>
<td>From Patient to Practitioner: Lessons Learned and Challenges Ahead</td>
</tr>
<tr>
<td>11:15 am</td>
<td>Implementation Panel Session</td>
<td></td>
</tr>
<tr>
<td>12:00 am</td>
<td>Lunch Break/Exhibitor Session (A-G Foyer)</td>
<td></td>
</tr>
</tbody>
</table>

#### Patient’s Perspective Symposium

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Presentation Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 pm</td>
<td>Raffaelle Pilla, Ph.D.</td>
<td>Bridging the Gap Between the Lab and Patients in Italy – a Multidisciplinary Approach</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Andrew Scarborough, B.Sc.</td>
<td>Beyond Ketosis: Managing Anaplastic Astrocytoma and Brain Tumor-Related Epilepsy with Metabolic Therapies – My Story</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Mike Dancer, M. Phil.</td>
<td>A Patient’s Perspective – Ketogenic Diet for Epilepsy</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>Conference Wrap-Up Panel &amp; Closing Session</td>
<td></td>
</tr>
</tbody>
</table>
Quest Keto is about to make ketogenic eating more delicious and more convenient than ever! The high-fat, moderate protein, and low-carb ketogenic (or “keto”) diet has earned a reputation for being complicated due to the strict macronutrient ratios required, but Quest Keto has changed all that. The Quest approach to making healthy eating fun is the missing ingredient for making keto an option for everyone.

LOW CARB, HIGH FAT

Quest Keto is about to make ketogenic eating more delicious and more convenient than ever! The high-fat, moderate protein, and low-carb ketogenic (or “keto”) diet has earned a reputation for being complicated due to the strict macronutrient ratios required, but Quest Keto has changed all that. The Quest approach to making healthy eating fun is the missing ingredient for making keto an option for everyone.

QUEST KETO SNACKS

Convenience, Sweet, Crunch, all the things you normally don’t have on a ketogenic diet.

For more information please visit [QuestKeto.com](http://QuestKeto.com)
Laszlo Boros, M.D., University of California, Los Angeles

Dr. Boros is currently a Professor of Pediatrics at UCLA and the Co-Director of the Stable Isotope Research Laboratory at the Los Angeles Biomedical Research Institute (LABIOMED) at the Harbor-UCLA Medical Center with a primary focus on studying cancer cell metabolism with the use of a specifically designed 13C-glucose tracer and mass spectroscopy. In 1995 he became the lead investigator to clinically apply stable isotope technologies to study diabetes and cancer growth in vitro and in animal models at UCLA. He is an expert in using metabolic profiling and mitochondrial nanomechanics to further understanding of particularly aggressive cancers. Dr. Boros is the recipient of the C. Williams Hall Outstanding Publication Award from the Academy of Surgical Research of the USA (1997), the Richard E. Weitzman Memorial Research Award from the University of California (2001), the Excellence in Clinical Research Award from the General Clinical Research Center at the Harbor-UCLA Medical Center (2004), Public Health Impact Investigator Award of the United States Food and Drug Administration (2011) and received a Best Publication Award from the Metabolomics Society and Springer Nature publisher (2014).

Mackenzie Cervenka, M.D., Johns Hopkins University

Dr. Mackenzie Cervenka is an Assistant Professor at Johns Hopkins University School of Medicine. She completed her undergraduate studies at the University of Virginia and received her medical degree from the University of Virginia School of Medicine. She then completed her internship in internal medicine and residency in neurology at the University of Maryland Medical Center. Dr. Cervenka completed a fellowship in epilepsy and clinical neurophysiology at Johns Hopkins and has remained there since 2008. She is Medical Director of the Johns Hopkins Adult Epilepsy Diet Center and the Epilepsy Monitoring Unit. The Adult Epilepsy Diet Center is the first of its kind, providing ketogenic diet therapies to adults with intractable epilepsy and smoothly transitioning children from a pediatric to an adult diet center. Dr. Cervenka’s research focuses the efficacy of ketogenic diets in the treatment of adults with epilepsy and refractory status epilepticus. She also studies functional brain mapping in preparation for epilepsy surgery.

Colin Champ, M.D., University of Pittsburgh Cancer Center

Colin Champ, MD, is an oncologist and assistant professor at the University of Pittsburgh Medical Center. His research focuses on diet, exercise, and lifestyle optimization for cancer treatment and prevention. His work has been published in many peer-reviewed journals, including the New England Journal of Medicine and Journal of Clinical Oncology. He has been featured by multiple media sources, including the National Institute of Health, Sanjay Gupta’s Gupta Guide on Medpage, and the Boston Globe. He is the author of Misguided Medicine and is an avid online blogger on a range of health-related and cancer-prevention topics.

Christos Chinopoulos, M.D., Ph.D., Semmelweis University

Dr. Christos Chinopoulos is an Associate Professor in the Department of Medical Biochemistry of Semmelweis University in Budapest Hungary, from where he also received his MD and PhD. He did his postdoc in the University of Maryland, Baltimore, where he studied mitochondrial mechanisms of neurodegeneration. In 2012, he was appointed as a “Momentum-Investigator” of the Hungarian Academy of Sciences. While researching on the mechanisms of mitochondrial impairment for various degenerative diseases and hypoxic conditions, it became evident that cancer may recruit the very same mechanisms in order to thrive during similar circumstances of anoxia and scarcity of exogenous metabolic substrates. Currently, he is focusing on the bioenergetic implications of mitochondrial substrate-level phosphorylation substantiated by the succinate-CoA ligase and adjuvant pathways, during anoxia or ETC dysfunction.
Conference Speakers

**Stephanie Ciarlone, Ph.D., University of South Florida**

Stephanie Ciarlone is a Postdoctoral Research Fellow in the Department of Molecular Pharmacology and Physiology at the University of South Florida (USF). She holds a Bachelor’s degree in Biology, Psychology, and Health Sciences from Guilford College in Greensboro, NC. She completed her graduate work at the University of South Florida where she earned a Master’s degree and Ph.D. in Medical Sciences. During her time as a graduate student she has served on the Executive Board of the Association for Medical Sciences Graduate Students from 2012 – 2015, holding the position of Vice President during the 2014 – 2015 academic year. She is currently in the laboratory of Dr. Edwin Weeber, where her research focuses on therapeutic options for Angelman syndrome with an emphasis on seizure treatment. Her findings have been presented at the annual Society for Neuroscience conference, where she received the SFN Trainee Professional Development Award. In 2016, she received the University of South Florida Dissertation Completion Fellowship and successfully defended her dissertation in November.

**Stephen Cunnane, Ph.D., University of Sherbrooke**

The main theme of Dr. Cunnane’s research is to use PET and MRI to study the impact of aging on brain structure and fuel metabolism and to apply this information towards preventive strategies that reduce the risk and limit the progression of Alzheimer’s disease. He has published over 300 peer-reviewed research papers and was elected to the French National Academy of Medicine in 2009. Dr. Cunnane has published five books including two on nutritional and metabolic constraints on human brain evolution - Survival of the Fattest: The Key to Human Brain Evolution (World Scientific 2005), and Human Brain Evolution: Influence of Fresh and Coastal Food Resources (Wiley, 2010).

**Dominic D’Agostino, Ph.D., University of South Florida**

Dominic D’Agostino is an Associate Professor in the Department of Pharmacology and Physiology at the University of South Florida. He is also a Senior Research Scientist at the Institute for Human & Machine Cognition. He holds a Ph.D. in Physiology and Neuroscience from Rutgers University. His research focuses on developing and testing metabolic therapies, including ketogenic diets, ketone esters, ketone supplements and metabolic-based drugs, to enhance neurological and physiological resilience under environmental extremes and to treat a broad range of disorders linked pathophysiologically to metabolic dysregulation, including seizures, neurological disorders, wound healing, muscle wasting and cancer.

**Patricia Daly, dipNT, mBANT, rCNHC**

Patricia Daly is a fully qualified nutritional therapist (dipNT, mBANT, rCNHC) and author based in Dublin, Ireland. Following her cancer diagnosis, she left her corporate career and started studying nutritional therapy, specializing in the area of Integrative Cancer Care. As a Swiss native, she regularly attends training courses in Switzerland and Germany, including at the renowned Tumor Biology Center in Freiburg, Germany. Patricia lectures at the Irish Institute of Nutrition and Health and regularly speaks at international conferences. In April 2016, she published the book “The Ketogenic Kitchen” with her co-author Domini Kemp.
Mike Dancer, M. Phil.

Mike’s world changed dramatically when - aged 34 and without warning - he collapsed in an epileptic seizure while working at the University of Birmingham, UK. It was his first. More followed. He was diagnosed with Temporal Lobe Epilepsy and was prescribed increasing amounts of anti-epilepsy drugs. These did not reduce the seizures and came with escalating side effects. He came across Dominic D’Agostino on the internet who suggested that Mike try a dietary approach to managing the seizures, through implementing & adapting nutritional ketosis - which had previously only been administered to children with epilepsy. Eight years later, Mike continues to use this dietary approach for managing seizures, through careful combination of exercise and diet.

David Diamond, Ph.D., University of South Florida

David Diamond received his Ph.D. in Biology in 1985, with a specialization in Behavioral Neuroscience, from the Center for the Neurobiology of Learning and Memory at the University of California, Irvine. He is a professor in the Departments of Psychology and Molecular Pharmacology and Physiology at the University of South Florida and is a Research Career Scientist at the Tampa Veterans Hospital, where he has directed his research program on post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). Dr. Diamond has also served as the Director of the USF Neuroscience Collaborative program and is a Fellow at the American Institute of Stress and the International Stress and Behavior Society. He has served on federal government study sections and committees evaluating research on the neurobiology of stress and memory, and has over 100 publications, reviews and book chapters on the brain and memory. He has served on the editorial boards of numerous medical journals and has received over 25 years of federally funded support for his research. In the past decade, Dr. Diamond has expanded his research program to include cardiovascular disease and nutrition. His controversial research is an extension of an advanced seminar he directs at the University of South Florida entitled “Myths and Deception in Medical Research”, which emphasizes the critical evaluation of methods and conflicts of interest in health-related research. In recent years he added to his list of publications controversial papers on diet, cholesterol and statins, including one paper published in the peer-reviewed medical journal “Expert Review of Clinical Pharmacology”, which described the deceptive practices employed by researchers promoting statins for the treatment of cardiovascular disease. Dr. Diamond has been invited to present his myth-busting views on nutrition and cholesterol at domestic and international conferences focusing on nutrition, cardiology, obesity and diabetes.

Vishwa Deep Dixit, D.V.M., Ph.D., Yale University

Vishwa Deep Dixit is a Professor of Comparative Medicine and Immunobiology at the Yale School of Medicine. He did PhD Research at University of Hannover, Germany and did his postdoctoral research at the NIH. Before joining Yale, he was a faculty member at the Pennington Biomedical Research Center, Baton Rouge. Dixit’s research is focused on Immunometabolism with the goal to reveal molecular targets that can be harnessed to control inflammation and immune dysfunction as a means to enhance the healthspan. He has discovered that prolongevity hormone FGF21 protects against thymic degeneration in aging and T cell senescence. His lab has helped define the role of the innate immune sensor NLRP3 inflammasome in aging, insulin-resistance, type 2 diabetes and immune-senescence. His lab identified that ketone metabolite β-hydroxybutyrate deactivates the NLRP3 inflammasome and thus serves as a therapeutic target to lower the NLRP3 inflammasome -dependent inflammatory diseases. His work has been published in prominent journals including Nature Immunology, Nature Medicine, Cell Metabolism, Cell Reports, PNAS, Journal of Clinical Investigation, etc. He has received numerous awards for his research including Fellows Award for Research Excellence by NIH (thrice), Nathan Shock Young Investigator Awards from National Institute on Aging and Gerontological Society of America, and Young Investigator award from Endocrine Society. He received Honorary Masters of Arts (MA) from Yale University in 2014. The Dixit Laboratory is funded in part by the US, National Institutes of Health.
**Brendan Egan, Ph.D., University College Dublin**

Brendan is Senior Lecturer in Sport and Exercise Physiology at Dublin City University, Ireland, and also holds a Visiting Associate Professor position at University College Dublin. He received his BSc Sport and Exercise Science from the University of Limerick in 2003, MSc Sport and Exercise Nutrition from Loughborough University in 2004, and PhD from Dublin City University in 2008, before completing two years of post-doctoral training with Prof. Juleen Zierath’s Integrative Physiology group at the Karolinska Institute, Sweden. His doctoral studies focussed on skeletal muscle adaptation to exercise, and in particular the continuity between acute molecular responses to individual bouts of exercise and adaptations induced by exercise training, whereas his post-doctoral training utilised animal models and in vitro cell systems to investigate the transcriptional regulation of skeletal muscle development and mechanisms of insulin resistance. His current research investigates the molecular regulation of skeletal muscle function and adaptation across the life course, with special interest in nutrition and exercise interventions to optimize performance in athletes and elderly. He continues to compete in elite level Gaelic Football and consults as a performance nutritionist to elite team sport athletes.

**Richard Feinman, Ph.D., State University of New York**

Richard David Feinman is Professor of Cell Biology (Biochemistry) at the State University of New York (SUNY) Downstate Medical Center in Brooklyn, New York. Dr. Feinman’s original area of research was in protein chemistry and enzyme mechanism, particularly in blood coagulation and related processes. His current interest in nutrition and metabolism, specifically in the area of diet composition and energy balance, derives from and continues to influence his teaching in the Medical School where he has been a pioneer in incorporating nutrition into the biochemistry curriculum. Dr. Feinman is the founder and former co-Editor-In-Chief (2004-2009) of the journal, Nutrition&Metabolism. He is principal author of the comprehensive review “Dietary carbohydrate restriction as the first approach in diabetes management: Critical review and evidence base” and his recent book “The World Turned Upside Down. The Second Low Carbohydrate Revolution” describes “How the science of carbohydrate restriction arising from a rag-tag collection of popular diets defeated the powerful low-fat army and became the default approach to health.” Dr. Feinman received his BA from the University of Rochester and he holds a PhD in chemistry from the University of Oregon.

**Balázs Györffy, M.S., Hungarian Academy of Sciences**

Balázs Györffy is an assistant research fellow in the Neuroimmunology Research Group of the Hungarian Academy of Sciences in Budapest, Hungary. He received his B.Sc. and M.Sc. degrees in biology and neuroscience, respectively, from Eötvös Loránd University in Budapest. He gained experience mostly in the field of molecular neuroscience, with emphasis on neuroproteomics. His current research focus is on the elucidation of molecular mechanisms in the background of the elimination of synapses under physiological circumstances and in neurodegenerative disorders, e.g., in Alzheimer’s disease.
Eugene Fine, M.D., Albert Einstein College of Medicine

Dr. Fine is Professor of Radiology (Nuclear Medicine) at the Albert Einstein College of Medicine in NYC. He obtained an M.S. in nuclear physics from U. of Pennsylvania in 1971, and an M.D. in 1976 from State University of New York, Downstate Medical Center. After residencies in Internal and Nuclear Medicine at Downstate affiliated programs he obtained certification from the American Boards of Internal and Nuclear Medicine in 1979 and 1981, respectively. He joined Einstein faculty in 1981, was promoted to Associate Professor in 1987 and to Professor in 1996. He was named Chairman of Nuclear Medicine at Jacobi Medical Center from 1997-2006 and Director of the M. Donald Blaufox Laboratory of Molecular Imaging from 2006-2012, and has been scientific consultant for the lab since that time.

Dr. Fine's early research focused on quantitation of heart and kidney function. On sabbatical at the Institute for Clinical Research in Pisa at 1993-4, Dr. Fine began studying PET scanning, and became especially interested in cancer imaging and the Warburg effect, which fascinated him since medical school. The effect provides the basis for 18F-fluorodeoxyglucose (FDG) diagnostic imaging as part of standard cancer care using PET scanning and explicitly demonstrates that many aggressive cancers depend on glucose/glycolysis for their energy supply.

Dr. Fine with his long-time colleague Dr. Richard Feinman have since 2003 pursued an hypothesis in which ketone bodies themselves can metabolically inhibit cancer ATP production and proliferation while leaving normal tissues unaffected. Dr. Fine and oncology colleagues at Einstein also performed and published a pilot study of 10 patients with aggressive cancers. For this 2012 pilot paper published in Nutrition (Elsevier), Dr. Fine was honored for excellence in metabolism research with The John M. Kinney Award in 2013 and by the Nutrition and Metabolism Society in the following year.

Jethro Hu, M.D., Cedars-Sinai Medical Center

Jethro L. Hu, M.D., came to Cedars-Sinai Medical Center in 2009 after completing a neuro-oncology fellowship at Massachusetts General Hospital/Dana-Farber Cancer Institute in Boston. He served as chief resident during his final year of residency in neurology at the University of California, Los Angeles, and received several awards and scholarships for academic achievement during his years in college and medical training.

Dr. Hu earned two bachelor’s degrees – one in molecular and cell biology, the other in political science – and was the founder and first president of the University of California, Berkeley Premedical Chapter of the American Medical Student Association from 1998 to 1999. He also served as president of the AMSA chapter at the University of California, San Francisco from 2001 to 2002. As part of the AMSA’s Washington Health Policy Fellowship Program, he was a health policy fellow in the office of Congressman Danny K. Davis in the summer of 2001.

Miriam Kalamian, Ed.M., M.S., C.N.S., Dietary Therapies LLC

Miriam Kalamian is a nutrition consultant, educator, and author specializing in the implementation of ketogenic therapies for cancer. Her current work and writing is focused on meeting the growing demand for the specialized tools and knowledge needed to personalize nutrition therapy. Beyond cancer, Miriam’s interest lies in integrating nutrition, metabolic therapies and lifestyle modifications to address neurodegenerative diseases and conditions associated with aging. Moving forward, she is committed to participating in collaborations that lead to the development and dissemination of best-practice guidelines.
Man’s Best Therapy for Man’s Best Friend

At KetoPet Sanctuary we are providing human-grade cancer therapies and diagnostics for Shelter Dogs with naturally occurring Cancers. The core of our mission is to feed our dogs a ketogenic diet – a diet that consists of high fat, medium protein and low carbohydrate.

Why a Ketogenic Diet?
In 1924 Nobel Laureate Dr. Otto Warburg observed that a cancer cell’s metabolism is different than healthy cells. Unlike healthy cells, cancer cells rely mainly on glucose for their energy needs.

What Does It All Mean?
Ketogenic diets put our dogs in a state that limits cancer cells from getting access to glucose – effectively starving the cancer.

How Do You Know Ketogenic Diets Work?
We are the only organization in the world outside of academia that uses Positron Emission Tomography/Computed Tomography (PET/CT) diagnostics for dogs. PET/CT is typically used in human medicine. The technology allows us to understand the efficacy of our therapies. The results we are producing are outstanding!

Donate Today!
Please visit our site for more information ketopetsanctuary.com
**Conference Speakers**

**Shannon Kesl, Ph.D., Epigenix Foundation**

Shannon has a B.S. in Medical Sciences from University South Florida and a M.S. and Ph.D. in Medical Sciences with concentration in Molecular Pharmacology and Physiology from the Morsani College of Medicine at University of South Florida. Shannon performed her dissertation research in the Laboratory of Nutritional and Metabolic Medicine under the co-mentorship of Dr. Dominic D’Agostino and Dr. Mack Wu. Her dissertation research focused on the effects of exogenous ketones for age-dependent impaired wound healing. During her time as a graduate student, she wrote multiple papers and a book chapter, presented her research at many national conferences, won numerous travel awards, and was a member of ASN, AAA, WHS, and APS societies. She is currently employed as a scientific advisor for the Epigenix Foundation, where her research focuses on the effects of metabolism and nutritional intervention on canine and human health.

**Rainer Klement, Ph.D., University of Würzburg**

Dr. Klement is an astronomer and medical physicist, health and fitness enthusiast and critical thinker. After 5 years as an astronomer studying the stellar build-up of our Milky Way galaxy, Dr. Klement started to work as a Medical Physicist in the Department of Radiation Oncology at the University Hospital of Würzburg, Germany. There he also started his research on ketogenic diets as supplementary cancer therapies. After two years in Würzburg, Dr. Klement took up a position at the Department of Radiation Oncology at the community hospital in his home town Schweinfurt. He was able to initiate a clinical study on the impact of a ketogenic diet intervention on body composition during radiation therapy (KETOCOMP) which is currently running. Besides that, he managed to make nutrition for cancer patients one of the clinic’s main focuses, with a strong emphasis on metabolically adapted and individualized high fat and low carbohydrate dietary advice. His main research interests now lie in the potential benefits that such diets can exhibit when combined with radiotherapy, as well as statistical modeling of factors influencing the outcome after certain high precision radiation therapy treatments called stereotactic body radiation therapy.

**Young Hee Ko, Ph.D., KoDiscovery, LLC**

Dr. Ko’s scientific research training commenced in the field of Nutritional Physiology at Iowa State University in Ames, Iowa and continued in the Department of Biophysics and Biochemistry at Washington State University in Pullman, Washington. Here she obtained her Ph.D. under the direction of Dr. Bruce A. McFadden. Dr. Ko’s thesis project included protein purifications from plants and bacteria, protein modifications, protein chemistry, enzyme mechanism and kinetics, and protein crystallization. Specifically, for crystallization of proteins, she worked closely with Dr. David Rice, a crystallographer and the Chair in the Department of Molecular Biology and Biotechnology at University of Sheffield, Sheffield, England. Following completion of her Ph.D. thesis, Dr. Ko joined Dr. Peter L. Pedersen’s research group at Johns Hopkins University, School of Medicine, as a post-doctoral fellow to expand her training in the basic science areas to more clinically relevant research areas, i.e., mitochondrial bioenergetics, cystic fibrosis, lung infections, and cancer. After her training in the above fields, she decided to place her effort on discovering highly effective agents for attacking many types of cancer. In 1999, she became focused in this laboratory on discovering novel anticancer agents, specifically those that can destroy the major fuel factories of cancers without harming the fuel factories of normal tissues. Currently, Dr. Ko has founded a small start-up company, *KoDiscovery, LLC, in Baltimore, Maryland to further develop 3BP as a potent anticancer drug option for cancer patients who have run out of all available treatment options or those patients who wish to be treated with 3BP as the first therapy.
**Conference Speakers**

**Andrew Koutnik, B.S., University of South Florida**
Andrew Koutnik received his Bachelor’s degree with Honors in Exercise Science from Florida State University. While at Florida State, Andrew was involved in 10 publications exploring how exercise, nutrition, supplementation, psychological status, and genetic defects in cardiac tissue impact both the cardiovascular and autonomic systems. Andrew received a Presidential Fellowship awards to join the Metabolic Therapeutic laboratory at USF College of Medicine to study wasting conditions in cancer. His current research revolves around cancer cachexia and potential therapeutic intervention to mitigate or attenuate this condition.

**Eric Kossoff, M.D., Johns Hopkins University**
Dr. Kossoff is a Professor of Neurology and Pediatrics at Johns Hopkins University in Baltimore, MD. He received his medical degree from SUNY at Buffalo School of Medicine in New York, followed by a residency in pediatrics at Eastern Virginia Medical School in Norfolk, Virginia. He completed a fellowship in child neurology and then pediatric epilepsy and clinical neurophysiology at The Johns Hopkins Hospital in Baltimore. He has been at Johns Hopkins since 1998. His research and clinical practice focuses on the diagnosis and treatment of childhood seizures and epilepsy, particularly treatments other than medications such as diet, neurostimulation and surgery. Currently the Medical Director of the Ketogenic Diet Center at Johns Hopkins, he is a world expert on the ketogenic diet and created the modified Atkins diet for children and adults in 2003. He is dedicated to bringing the use of diet therapies for neurologic disorders to the entire world and is the head of a Task Force within the International League Against Epilepsy to help achieve this goal. He is a coauthor of Ketogenic Diets: Treatments for Epilepsy and Other Disorders. Dr. Kossoff is also published in the fields of Sturge-Weber syndrome, the interaction between migraine and epilepsy in children, infantile spasms, Doose syndrome, and benign rolandic epilepsy.

Dr. Kossoff is also very involved in teaching and mentorship and is the Director of the Pediatric Neurology Residency Program at Johns Hopkins.

**Zsolt Kovács, Ph.D., University of West Hungary**
Dr. Zsolt Kovács is an associate professor at University of West Hungary (Savaria Campus, Szombathely, Hungary). Dr. Kovacs received his M.Sc. in biology from József Attila University (Szeged, Hungary) and Ph.D. in molecular biology from Eötvös Loránd University (Budapest, Hungary). He is the teacher of Neurochemistry and Animal anatomy in Savaria Campus. Dr. Kovacs is the Member of the VATT of the Hungarian Academy of Sciences (MTA VATT), the Hungarian Neuroscience Society (MITT), and the Federation of European Neuroscience Societies (FENS).

Dr. Kovács’ research is devoted to the investigation of distribution and functions of nucleosides in the brain as well as links between neuroimmunological reactions and pathomechanism of absence epilepsy. Research from his laboratory (http://neuroepilgroup.hu) suggests that (i) there is an area-, age- and gender-dependent distribution of nucleoside levels in the brain, (ii) purine and pyrimidine nucleosides, such as guanosine and uridine as well as their analogues could be potentially effective drugs for treatment of human absence epilepsy, (iii) there is a crosstalk between lipopolysaccharide-induced proinflammatory cytokine system, glutamatergic system, GABAergic system and adenosinergic system, in which non-adenosine nucleosides may have modulatory functions and (iv) lipopolysaccharide injection into freely moving absence epileptic rats, which increases epileptic activity, is applicable to investigate links between inflammation and absence epilepsy genesis. Dr. Kovács’ current research is also focused on investigation of the effect of ketogenic supplementation on absence epileptic activity in an animal model of human absence epilepsy Wistar Albino Glaxo Rijswijk (WAG/Rij) rats.
Valter Longo, Ph.D., University of Southern California

Dr. Longo is the Edna M. Jones Professor of Gerontology and Biological Sciences, and Director of the Longevity Institute at the University of Southern California – Davis School of Gerontology, Los Angeles. He is also a Senior Group Leader at the International Foundations of Medicine (IFOM) and holds four professorships across top EU academic centers.

Dr. Longo’s studies focus on the fundamental mechanisms of aging in simple organisms, mice and humans. The Longo laboratory has identified several genetic pathways that regulate aging in simple organisms and reduce the incidence of multiple diseases in mice and humans. His laboratory also described both dietary and genetic interventions that could reverse the course of Diabetes and Alzheimer’s and protect cells and improve the treatment of cancer and other diseases in mammals. Dr. Longo’s most recent studies are on dietary interventions that can affect stem cell-based regeneration to promote longevity in mice and humans. The Longevity Institute in Los Angeles, directed by Dr. Longo, includes over 40 faculty members focused on topics ranging from regeneration to dietary interventions aimed at improving health and lifespan in the near future. Among the accolades received by Dr. Longo are the 2010 Nathan Shock Lecture Award from the National Institute on Aging (NIA/NIH) and the 2013 Vincent Cristofalo “Rising Star” Award in Aging Research from the American Federation for Aging Research (AFAR).

Dr. Longo is recognized as a global leader in aging and nutrition. With more than 106 peer reviewed publications in journals like Science, Nature, Cell, JAMA, Circulation, Cancer Cell, Journal of Translational Medicine, etc. He is recognized by Time Magazine, with three features in less than two years, as Longevity Guru. He is one of the most recently featured scientists by global media and news feeds.

Dr. Longo was born and raised in Genoa, Italy and received his undergraduate degree from the University of North Texas, where he majored in biochemistry with a minor in jazz performance. He received his Ph.D. in Biochemistry from the University of California, Los Angeles (UCLA) in 1997 and his postdoctoral training in the Neurobiology of Aging and Alzheimer’s Diseases at USC. He started his independent career in 2000 at the University of Southern California, School of Gerontology, one of the first and leading programs for aging research and education.

Susan Masino, Ph.D., Trinity College

Susan A. Masino is the Vernon Roosa Professor of Applied Science at Trinity College. Her research is focused on adenosine, an endogenous molecule that promotes homeostasis and links between metabolism and brain activity. She proposed that adenosine is a key mechanism underlying ketogenic diet therapy; based on this, her research spans multiple conditions. Dr. Masino is also dedicated to educational, environmental and public policy issues affecting brain health.

Mary Newport, M.D.

Mary T. Newport, M.D. grew up in Cincinnati, Ohio, USA and was educated at Xavier University and University of Cincinnati College of Medicine, both in Cincinnati, Ohio. She is board certified in pediatrics and neonatology, and completed her training at Children’s Hospital Medical Center in Cincinnati, and Medical University Hospital in Charleston, SC. She practiced neonatology in Florida for thirty years and was founding medical director of two newborn intensive care units in the Tampa Bay area. Dr. Newport now practices at the opposite end of the spectrum, providing care for hospice patients in the Tampa Bay area of Florida.

Dr. Newport was also caregiver for fifteen years for her husband of forty-three years, Steve, who suffered from early onset Alzheimer’s disease and died in January 2016. They have two daughters and a grandson. She is author of Alzheimer’s Disease: What If There Was a Cure? The Story of Ketones, now in its second edition, which has been translated into French, German, and Japanese, and also author of The Coconut Oil and Low Carb Solution for Alzheimer’s, Parkinson’s and Other Diseases. Dr. Newport has been an invited speaker on this subject for symposia and conferences in the USA, Canada, France, Greece, Germany, and Japan, University of South Florida, the American College of Nutrition, the Institute for Human and Machine Cognition, the Fellowship in Anti-Aging and Regenerative Medicine, the International College of Integrative Medicine, Weston A. Price Foundation, and numerous lectures for university students and for the public.
The Nisshin OilliO Group, Ltd.

Proud to be a part of the Second Annual Conference On Nutritional Ketosis & Metabolic Therapeutics


Sponsors
Raffaele Pilla, Pharm D., Ph.D., University of Salerno

Raffaele Pilla, Pharm.D., Ph.D., Doctor Europaeus, received his Master’s degree in Pharmacy at G. d’Annunzio University in Chieti-Pescara, Italy in 2005, where he also served internships at the Cell Physiology Laboratory and Molecular Biology Laboratory. Prior to his degree, he was an Erasmus Student at Faculté de Pharmacie de Reims in Reims, France. He received his Doctor Europaeus in 2010 from Pitié-Salpêtrière Institute in Paris, France. Also in 2010, he received his Ph.D. in Biochemistry, Physiology, and Pathology of Muscle at G. d’Annunzio University in Chieti-Pescara, Italy. He was hired as a Postdoctoral Scholar in the Department of Pharmacology and Physiology at the University of South Florida in Tampa, on two research grants respectively funded by the Office of Naval Research (US Navy) and Divers’ Alert Network. He has written and lectured widely on his experiences. Dr. Pilla has been involved in ongoing research at the University of South Florida with the use of ketone esters. The initial work, funded by the Office of Naval Research, focused on using ketone esters to prevent CNS oxygen toxicity. Dr. Pilla is working to coordinate efforts in the United States and Italy to expand the ketone ester research to other conditions such as epilepsy and cancer and its use as an alternative metabolic fuel. Dr. Pilla has also served extensively in various international medical missions, orphan and homeless programs, emergency medicine rescue and training, and animal rescue and fostering. He is fluent in Italian, English, French, and Spanish. He has a special interest in journalism and photography, and he enjoys sailing, SCUBA diving, ultralight airplane piloting, soccer, volleyball, jogging, and motorcycles.

Ron Penna, B.S., Epigenix Foundation

As co-founder of Quest Nutrition and the 501(c)(3) Epigenix Foundation, Ron has a deep passion for nutrition and its vastly underappreciated role in human health. His role as CEO of Quest Nutrition allows him the opportunity to learn from nutrition science thought leaders and to use that information to change food manufacturing so that it impacts human health positively. A serial entrepreneur in many diverse fields including software and credit card processing, one of his current objectives is to determine the place of ketogenic diets in the treatment of cancer and enhancing human performance.

Angela Poff, Ph.D., University of South Florida

Angela Poff is a Research Associate in the Department of Molecular Pharmacology and Physiology at the University of South Florida in Tampa, FL. She holds a Bachelor’s degree in Biochemistry and Molecular Biology from Hendrix College in Conway, AR. She completed her graduate work at the University of South Florida where she earned a Master’s degree and Ph.D. in Medical Sciences. During that time, Angela served on the Executive Board of the Association for Medical Sciences Graduate Students at USF from 2010 – 2014, serving as President of the board from 2012 – 2013. Angela worked as a postdoctoral research scholar in the Department of Molecular Pharmacology and Physiology at USF from 2014 – 2015. Her research focuses on the development and characterization of metabolic-based, non-toxic therapies for cancer and neurological disorders. She has presented her work at many national and international scientific conferences, including the Keystone Symposia on Tumor Metabolism, Federation of American Societies for Experimental Biology, and the Global Symposium on Ketogenic Therapies. She is on the planning committee of the annual Conference on Nutritional Ketosis and Metabolic Therapeutics and travels to give lectures to varied audiences on science and research related to ketosis. Angela is passionate about teaching and worked as an adjunct professor at Hillsborough Community College in Tampa where she instructed night classes in Anatomy and Physiology during her doctoral and postdoctoral tenure. She currently works as an adjunct professor in the Department of Health Sciences and Human Performance at the University of Tampa where she teaches a Master’s course on Cellular Bioenergetics and Metabolism. In her free time, she enjoys spending time with her husband, Franklin, and her two dogs and three cats.
A Metabolic Method For Treating Cancer
Vios Health is an innovative health technology company that is designing, developing and commercializing ketogenic cancer treatment solutions allowing individuals to open another front in the battle against cancer. Bring your questions to our booth, we’re happy to chat. 

viosthhealth.com
1.855.219.8337
info@viosthealth.com

Dr. Reinwald Healthcare US
The ketogenic diet in cancer: a plea for a paradigm shift.

- If cancer feeds predominantly off sugars and the body’s own protein, a nutritional intervention in the form of the ketogenic or hyperketogenic diet is productive, especially when combined with the nutritional building block of MyAMINO. Any responsible therapist should therefore draw the following conclusions from these findings which define who we are as a company:
  - We are in the health business – “MAKE AMERICA HEALTHY AGAIN”
  - Supply as little carbohydrate and simple sugars as possible
  - Protect the body’s own protein through sufficient amount of dietary protein (MyAMINO is recommended due to its unique properties in almost no delivering any nitrogen waste and energy)
  - Administer enough fat, particularly fats containing medium-chain fatty acids (for example, coconut oil)

In addition: Hippocrates stated, that all diseases have their origin in the gut, and if we are to eradicate disease, we need to balance the gut, which at the same time means supporting our immune system. We are able to do this by:
  - Ketogenic diet with MyAMINO
  - Bravo Probiotic Yogurt
  - Vitamin D oral emulsion to support our immune system called, “Rerum”
  - Depending on the individual, we also supply supplements which provide minerals and/or support the mitochondria and digestive system.
  - DETOX

“More die in the United States of too much food than too little.” – John Kenneth Galbraith
Andrew Scarborough, B.Sc., University of Westminster

Andrew Scarborough is a proactive cancer patient, researcher, science communicator and public health advocate. He is currently studying for a degree in Human Biology and Medical Science at the University of Westminster with a research focus on neuroscience and cancer biology. Since being diagnosed with a hemorrhagic Anaplastic Astrocytoma brain tumour in 2013, Andrew has developed a range of resources to inform patients of the emerging science behind personalised metabolic therapies.

A key focus of interest for Andrew is manipulation of fatty acids on the ketogenic diet in an attempt to alter the dysregulation of lipids seen in brain tumours. Andrew mixes practical experience of metabolic therapies with a detailed understanding of its potential for cancer management and seizure control at the cellular level. His research project at university aims to observe epigenetic changes of ketone esters in combination with specific anti-epileptic drugs in vitro. The aim is to mimic a typical patient scenario and assess any potential synergistic benefits of these agents that have clear survival benefits in isolation for these patients.

Brent Reynolds, Ph.D., University of Florida

Brent A. Reynolds, Ph.D. attended the University of Calgary where he received his M.Sc. and Ph.D. in 1989 and 1994, respectively. While working on his Ph.D. thesis, Reynolds discovered the existence of stem cells in the adult mammalian brain, a finding that overcame a century old dogma that the mature brain did not have the capacity to repair itself. After graduating, Reynolds co-founded the first neural stem cell company (NeuroSpheres, Ltd.) where he was a Director and VP-Research. Here he developed a strong patent portfolio in the neural stem cell field developing and protecting protocols related to the application of stem cell technology in brain repair. Today, these patents and technology have been licensed to numerous biotechnology companies that are testing the efficacy in over half a dozen clinical trials for diseases such as spinal cord injury, stroke, ALS and pediatric disorders. After a brief hiatus, where Reynolds studied and practiced Chinese Medicine, he returned to industry and assisted in the development and launching of several products in the stem cell field while working in Vancouver, Canada. In 2004 Reynolds returned to academic science as a Professor at the Queensland Brain Institute at the University of Queensland in Australia where he continued to refining the application of neural stem cells for repairing the damaged brain.

In 2008, Reynolds was recruited to the Dept. of Neurosurgery at the University of Florida and has focused his efforts on studying aggressive pediatric and adult brain cancer and developing novel translational approaches to combat this lethal disease. Working with a multidisciplinary group of scientists the team is taking the unique approach that cancer can be managed as a chronic disease by applying the principles that have been used in ecology to manage wildlife and pest populations. Based on the lessons learned over the past 80 years by ecologists, the team is focusing on using multimodal low toxicity therapeutics to enforcing a stable tumor population that exists below a threshold that has any harmful effects. Reynolds has more than 70 publications including papers in Science, Nature and Cell with several manuscripts receiving over 1000 citations. In addition, he is an inventor on 19 granted US patents and numerous patent applications. Reynolds is currently the CEO of Prana Therapeutics, Inc., a Professor in the Dept. of Neurosurgery at the University of Florida, Adjunct Professor at the University of New South Wales, Sydney, Australia, an Honorary Professor at the Queensland Brain Institute, Australia and Program Director for StepAhead, Australia. NIH, NHMRC and numerous foundations have funded his lab.

Keith Runyan, M.D., Northside Hospital

Keith Runyan, MD is medical doctor who practiced clinical medicine in the areas of emergency medicine, internal medicine, nephrology, and obesity medicine. In 1998, he was diagnosed with type 1 diabetes and subsequently followed the conventional advice to treat his condition for the next 14 years. Although his glycemic control was at “recommended levels” of HbA1c of 6.5-7%, he was disturbed by frequent hypoglycemic episodes. After starting regular exercise to train for triathlons in 2007, his glycemic control actually worsened from taking sports gels to prevent hypoglycemia. When he contemplated doing an ironman distance triathlon in 2011, he sought a better method to control his diabetes. He came across the ketogenic diet in 2012 and experienced a rapid and remarkable improvement not only in glycemic control but also in preventing hypoglycemia and its symptoms. He completed the ironman distance triathlon in 2012 without sugar, food, or hypoglycemia while in nutritional ketosis. He is now an advocate for the use of the ketogenic diet for management of diabetes and has authored books explaining its use and benefits. He documents his results on his blog at ketogenicdiabeticathlete.wordpress.com.

Andrew Scarborough, B.Sc., University of Westminster

Andrew Scarborough is a proactive cancer patient, researcher, science communicator and public health advocate. He is currently studying for a degree in Human Biology and Medical Science at the University of Westminster with a research focus on neuroscience and cancer biology. Since being diagnosed with a hemorrhagic Anaplastic Astrocytoma brain tumour in 2013, Andrew has developed a range of resources to inform patients of the emerging science behind personalised metabolic therapies.

A key focus of interest for Andrew is manipulation of fatty acids on the ketogenic diet in an attempt to alter the dysregulation of lipids seen in brain tumours. Andrew mixes practical experience of metabolic therapies with a detailed understanding of its potential for cancer management and seizure control at the cellular level. His research project at university aims to observe epigenetic changes of ketone esters in combination with specific anti-epileptic drugs in vitro. The aim is to mimic a typical patient scenario and assess any potential synergistic benefits of these agents that have clear survival benefits in isolation for these patients.
A baking/cooking mix created for the Ketogenic Diet

KetoCuisine
877-850-0985
www.medica-nutrition.com
www.KetoCuisine.com

However, the text is not fully visible, and there seems to be an image of the conference program or brochure with the text cut off. It is a promotion for a conference on integrative oncology, emphasizing targeted, metabolic, energetic, and immunologic therapies.

For Physicians and all Medical Professionals:
April 27-29, 2017 at San Diego's Town and Country Resort

- The longest-running and highest-rated conference for cancer and chronic disease!
- This “Don’t Miss” Conference offers the best bang-for-the-buck.
- Includes 3 organic meals/day with purified air and water for a healthy environment

To register and for more info: www.bestanswerforcancer.org or contact admin@bestanswerforcancer.org
Thomas Seyfried, Ph.D., Boston College

Thomas N. Seyfried is Professor of Biology at Boston College, and received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He did his undergraduate work at the University of New England where he recently received the distinguished Alumni Achievement Award. He also holds a Master's degree in Genetics from Illinois State University, Normal, IL. Thomas Seyfried served with distinction in the United States Army's First Cavalry Division during the Vietnam War, and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine, and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and he recently received a Lifetime Achievement Award from the Academy of Complimentary and Integrative Medicine. He presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro. Dr. Seyfried has over 170 peer-reviewed publications and is author of the book, Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press). His full list of peer-reviewed publications can be found on PubMed (http://www.ncbi.nlm.nih.gov/pubmed).

Jeff Volek, Ph.D., R.D., The Ohio State University

Dr. Jeff Volek is a registered dietitian and professor in the Department of Human Sciences at the Ohio State University. For the last two decades, he has performed cutting edge research elucidating how humans adapt to diets restricted in carbohydrate with a dual focus on clinical and performance applications. His work has contributed to the existing robust science of ketones and ketogenic diets, their use as a therapeutic tool to manage insulin resistance, plus their emerging potential to augment human performance and resiliency. Dr. Volek has secured several million dollars in research funds from federal sources, industry, and foundations. He has been invited to lecture on his research over 200 times at scientific and industry conferences in a dozen countries. His scholarly work includes 300+ peer-reviewed scientific manuscripts and five books.

Adrienne Scheck, Ph.D., Barrow Neurological Institute

Adrienne C. Scheck, PhD, is an Associate Professor at the Barrow Neurological Institute in Phoenix Arizona. She is also an Adjunct Professor in the School of Life Sciences at Arizona State University and an Associate Investigator in the Cancer Biology Program at the Arizona Cancer Center of the University of Arizona. Dr. Scheck received her undergraduate degree from the University of Rochester in NY and her PhD from Rensselaer Polytechnic Institute in Troy, NY. After a postdoctoral fellowship in viral oncology at the Pennsylvania State College of Medicine in Hershey, Pennsylvania, she moved to Memorial Sloan-Kettering Cancer Center to study AIDS-related dementia. She began her studies of brain tumors while at Sloan-Kettering and moved to the Barrow Neurological Institute in 1989.

Current work in her laboratory has 2 major goals. The first is to devise novel therapeutic regimens to improve survival and minimize side effects for patients with malignant brain tumors. To this end, her laboratory has been studying the use of the ketogenic diet (KD) for the treatment of malignant brain tumors. Their work has shown that the KD reduces the growth of malignant brain tumors through a variety of mechanisms, and it potentiates the effect of radiation and temozolomide chemotherapy. They have recently shown that a KD enhances the anti-tumor immune response. These preclinical studies have led to a clinical trial for patients with glioblastoma multiforme (www.clinicaltrials.gov NCT02046187). The second main goal of her research is to identify markers that improve on the current methods of diagnosis and prognosis for this devastating disease. In addition to her love for horses, one of Adrienne’s pet projects comes from her interest in science education. Her laboratory team includes 7-10 high school students and college undergraduates. She directs a program that places high school students in research laboratories around the Phoenix area and gives Cancer Biology lectures to area high school and college students.
Eric C. Westman, M.D., M.H.S., Duke University

Dr. Westman received his MD from the University of Wisconsin/Madison, completed an internal medicine residency and chief residency at the University of Kentucky/Lexington, and completed a General Internal Medicine Fellowship at Duke University, which included a Masters Degree in clinical research. He has been at Duke since 1990, has over 90 peer-reviewed publications, and is currently the Director of the Duke Lifestyle Medicine Clinic. He is Chairman of the Board of the Obesity Medicine Association (formerly, the American Society of Bariatric Physicians) and a Fellow of the Obesity Medicine Association and the Obesity Society. He is author of the New York Times Bestseller The New Atkins for a New You, Cholesterol Clarity, and Keto Clarity.

Harry T. Whelan, MD, Medical College of Wisconsin

Harry T. Whelan, MD, believes in a translational patient care philosophy, bringing the latest research discoveries from his laboratory bench to the patient’s bedside. Dr. Whelan is the Bleser Family Endowed Chair in Neurology with Children’s Hospital of Wisconsin, Professor of Neurology (Pediatrics), Director of the Hyperbaric Medicine Unit, and recipient of the Neuro-Oncology American Cancer Society Clinical Oncology Career Development Award from Vanderbilt University. He has been inducted into the NASA Space Technology Hall of Fame for his research into the use of near-infrared light for wound healing and the treatment of brain tumors and neurofibromatosis using photodynamic therapy. Dr. Whelan is also funded by the National Institutes of Health in a study of neurodegenerative disease, traumatic brain injury and other childhood traumas. The Defense Advanced Research Projects Agency (DARPA) is funding his research in neurological ischemia, traumatic brain injury (TBI), reperfusion and stroke, which affects many children with congenital heart disease. Dr. Whelan presented this translational bench-to-bedside research to the United States Congress at the NASA Spin-off Day on Capitol Hill as an example of how space research is helping patients. Dr. Whelan holds the rank of Captain and is a Diving Medical Officer in the U.S. Navy, a consultant to the Navy Experimental Diving Unit with clinical and research experience in Hyperbaric Medicine, wound care and combat casualty care. He has over 100 publications, including cancer, laser, LED and diving/hyperbaric studies.

Jacob Wilson, Ph.D., Applied Science and Performance Institute

Dr. Jacob Wilson, Ph.D., CSCS*D is a researcher and CEO of Applied Science and Performance Institute, a 21 thousand square foot performance and research facility dedicated to novel training and nutrition strategies to optimize human performance and longevity. With over 200 peer-reviewed papers, book chapters and abstracts Dr. Wilson has turned the focus of his research onto the cellular, molecular, and whole body changes in muscle size, strength, and power in response to ketogenic dieting and supplemental ketones in varying populations. Dr. Wilson was recently awarded the NSCA’s Terry J. Housh young investigator of the year award. Moreover he and his lab have been featured in the movie Generation Iron, which came out in theaters in 2013 and was aired on ESPN and in the sequel which will air in theaters in late 2017.

Beth Zupec-Kania, R.D., The Charlie Foundation

Beth Zupec-Kania is a Registered Dietitian and Nutritionist who has promoted safe and effective ketogenic therapies since 1991. She’s managed ketogenic diets in individuals with epilepsy, autism, multiple sclerosis, mitochondrial, metabolic, and rare genetic disorders, migraine headache, Parkinson’s disease, and various cancers. She’s authored over 50 publications, co-organized global symposiums and is the designer of KetoDietCalculator, a web-based program for calculating ketogenic diets, has provided ketogenic training to 180 medical centers worldwide, and is a consultant to The Charlie Foundation.
THANK YOU TO OUR SPONSORS!
THANK YOU TO OUR SPONSORS!
THANK YOU...

...for joining us.
See you next year!

METABOLIC THERAPEUTICS